Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Illinois for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Illinois only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Illinois (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Orsini Pharmaceutical Services, LLC (NPI 1073608998)

Field	Value
Entity Type	Organization
Organization	Orsini Pharmaceutical Services, LLC
Address	1107 Nicholas Blvd
City	Elk Grove Village
State	IL
ZIP	60007
Taxonomy	Specialty Pharmacy
NPI Enumerated	October 4, 2006

Payer Source	Total Paid
Medicaid	$187.5M
Medicare	$0

Key Findings

ORSINI PHARMACEUTICAL SERVICES, LLC has no Medicare billing on file and is effectively a single-payer Medicaid operator for its publicly reported claims, with Total Medicaid revenue of $187.5M. The absence of Medicare activity means analyses of payer mix should treat Medicaid as the sole measurable government payer for this NPI.

Revenue is highly concentrated in a very small set of high-cost drug codes: the precomputed top three codes account for 89.5% of the provider's Medicaid revenue. Specifically, J1428 accounts for $92.3M (49.2%), J1426 accounts for $65.6M (35.0%), and J0584 accounts for $9.9M (5.3%) of the $187.5M total.

The code mix signals a specialty pharmacy model focused on high-cost, low-volume injectable biologic therapies and orphan drugs: J1428 (eteplirsen), J1426 (casimersen) and J0584 (burosumab-twza) are all specialty injectables with very high average paid amounts per claim, consistent with rare-disease treatment dispensing rather than mass retail pharmacy activity. The presence of infusion and home-visit codes (99601/99602 and S9379) further indicates the organization provides or coordinates administration and home-infusion services alongside specialty dispensing.

Per-claim economics underline the high-cost nature of the business: J1426 shows an avg paid/claim of $31833 across 2.1K claims, J1428 shows $20923 avg across 4.4K claims, and J0584 shows $19317 avg across 510 claims. These high average payments per claim, combined with the claim counts reported, explain how a concentrated set of codes produces the majority of the $187.5M Medicaid revenue without a broad code portfolio.

Competitive standing in-state for the top orphan drug codes is notable because ORSINI is the sole reported Medicaid filer for several of its highest-revenue codes: J1428, J1426 and J0584 each rank #1 of 1 providers in-state (0th percentile; no state peer volume comparison available). That ranking pattern should be interpreted as exclusive reported activity for those codes in the state data rather than as a traditional percentile-based peer comparison.

For addiction-treatment depot formulations and related products, ORSINI reports material but smaller Medicaid volumes: J2315 (naltrexone depot) accounts for $9.2M (4.9%) over 7.7K claims and ranks #1 of 2 providers in-state (100th percentile; typical, unremarkable volume), while Q9992 and Q9991 together contribute $4.7M and $3.7M respectively and are each reported as #1 of 1 providers in-state (0th percentile; no state peer volume comparison available). These entries suggest an additional service line supporting extended-release opioid-dependence treatments alongside the dominant rare-disease portfolio.

Operationally, the provider also reports home-infusion administration and supply codes at modest revenue levels (99601: $412.1K; 99602: $428.8K; S9379: $186.5K), which indicates active provision or coordination of infusion visits and per-diem pharmacy services. While these lines make up only a small fraction of total Medicaid revenue, they are consistent with a full-service specialty pharmacy that combines product dispensing with hands-on infusion and care coordination.

The provider's NPI was enumerated on 2006-10-04 (~20 years ago), indicating an established presence in the market. That tenure, combined with concentrated, high-dollar Medicaid reporting and sole-provider reporting for multiple top codes in-state, supports characterizing ORSINI as an established specialty pharmacy operator with a narrow but financially significant set of Medicaid drug lines.

Medicaid: Complete Services Breakdown

Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.

12 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1428	Injection, eteplirsen, 10 mg	4,410	$20,920	$92.3M
J1426	Injection, casimersen, 10 mg	2,060	$31,830	$65.6M
J0584	Injection, burosumab-twza 1 mg	510	$19,320	$9.9M
J2315	Injection, naltrexone, depot form, 1 mg	7,730	$1,190	$9.2M
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	3,260	$1,440	$4.7M
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	2,660	$1,400	$3.7M
J3490	Unclassified drugs	30	$35,420	$920.9K
99602	The provider visits the patient at home to provide an infusion or administer a specialty drug. Use this code for each additional hour of the visit after the first two hours.	2,340	$180	$428.8K
99601	The provider visits the patient at home to provide an infusion or administer a specialty drug. Use this code for up to the first two hours of a visit.	4,040	$100	$412.1K
S9379	Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and…	2,330	$80	$186.5K

Showing 1–10 of 12

Medicaid: Competitive Analysis & Benchmarks

How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.

Claims Volume vs. Illinois Distribution

Orsini Pharmaceutical Services, LLC — 4 of 12 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Illinois

Full comparison — all codes billed, vs. Illinois median

12 rows

CPT/HCPCS Code	Description	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J1428	Injection, eteplirsen, 10 mg	1	10	4,410	$20,920	$92.3M
J1426	Injection, casimersen, 10 mg	1	10	2,060	$31,830	$65.6M
J0584	Injection, burosumab-twza 1 mg	1	10	510	$19,320	$9.9M
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	1	10	3,260	$1,440	$4.7M
J2315	Injection, naltrexone, depot form, 1 mg	1	10	3,890	$1,180	$4.6M
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	1	10	2,660	$1,400	$3.7M
99601	The provider visits the patient at home to provide an infusion or administer a specialty drug. Use this code for up to the first two hours of a visit.	1	10	2,400	$120	$284.1K
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	9	10	870	$60	$247.4K
99602	The provider visits the patient at home to provide an infusion or administer a specialty drug. Use this code for each additional hour of the visit after the first two hours.	1	10	1,230	$180	$227.1K
J3032	Injection, eptinezumab-jjmr, 1 mg	1	10	60	$2,160	$123.3K

Showing 1–10 of 12

Nearby Providers

Other providers in the same ZIP code as Orsini Pharmaceutical Services, LLC, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kenneth Young Center	IL	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$48.5M
Village Of Elk Grove Village	IL	Land Ambulance	$433.7K	$6.2M
Home Sweet Home Supportive Living LLC	IL	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$3.9M
Peter Bernhardt	IL	Hematology (Pathology) Physician	$40.4K	$2.2M
Meditech Clinical Services, Inc.	IL	Clinical Medical Laboratory	$1.3M	$702.2K
Steven Kanter	IL	Hematology & Oncology Physician	$1.7M	$24K
Medlab Inc	IL	Clinical Medical Laboratory	$403.1K	$1.2M
Bruce Johnson	IL	Rheumatology Physician	$1.2M	$0
Gary Gordon	IL	Hematology & Oncology Physician	$1M	$5.8K
Daniel Kuesis	IL	Sports Medicine (Orthopaedic Surgery) Physician	$963.9K	$11.4K

Orsini Pharmaceutical Services, LLC — Billing Profile & Reimbursement Data

Sign up for Orsini Pharmaceutical Services, LLC — Billing Profile & Reimbursement Data policy alerts

Orsini Pharmaceutical Services, LLC — Billing Profile & Reimbursement Data

Sign up for Orsini Pharmaceutical Services, LLC — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicaid: Total Revenue Breakdown by CPT/HCPCS Code

Medicaid: Complete Services Breakdown

Medicaid: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References